The Daily Fuckup

On July 28, the Trump White House tried to turn Kodak into a pandemic success story. The administration announced a $765 million federal loan intended to help the company move into pharmaceutical manufacturing, presenting it as a bold step toward rebuilding domestic supply chains during a public health emergency. President Trump helped sell the deal at a press briefing, praising it as evidence of extraordinary leadership and positioning it as a practical answer to COVID-era shortages. For a few minutes, the messaging was clear enough: Washington was backstopping industry, America was making things again, and the president wanted credit for both. Then the questions started, and the whole thing began to look less like industrial strategy than a political stunt with a government seal on it.

The problem was not simply that Kodak was an unusual choice. The company was best known for cameras, not chemical manufacturing, and the announcement came with just enough surprise to make the optics immediately suspicious. Its stock had already been volatile, which only sharpened concerns about whether the timing and handling of the news gave anyone an unfair advantage. Once the loan became public, lawmakers, market watchers, and ethics-minded critics all began circling the same basic issues: who knew about the deal ahead of time, who benefited from the announcement, and whether the process had been handled with any real care. In a year when emergency spending was already being rushed out the door, the Kodak episode raised the ugly possibility that federal relief had become a kind of favor factory for well-connected firms. That was especially damaging because the White House had framed the move not as a narrow bailout but as a showcase for its pandemic industrial policy. Instead of looking like a serious supply-chain intervention, it looked like the administration had confused a press event with a procurement process.

That confusion mattered because the Trump team had spent months insisting it could manage the pandemic with urgency, competence, and dealmaking flair. The Kodak announcement undercut that claim in a way that was hard to miss. Federal pandemic policy was already marked by mixed messaging, improvisation, and a recurring sense that important decisions were being made on the fly. This deal added the distinct impression that public power and private advantage were being mixed together without enough guardrails. Democrats in Congress quickly started asking how the loan had been approved and whether any officials had properly vetted Kodak’s readiness, financing, and governance. The concern was not merely philosophical. If a company is being handed a giant federal lifeline in the middle of a crisis, there should at least be a record showing that basic due diligence happened. Instead, the announcement landed like a triumphal shout from a White House that seemed addicted to spectacle and impatient with process. Even people sympathetic to the idea of rebuilding domestic manufacturing had reason to wonder why this was the vehicle chosen to carry that message.

The larger ethical alarm came from how neatly the episode fit a broader Trump-era pattern. Critics saw the announcement as another example of the administration blurring the line between public authority and private gain, then acting surprised when people noticed. That is what made the Kodak story so combustible. It was not just that the company was an odd fit for pharmaceutical production, or that the administration appeared eager to celebrate the deal before the scrutiny had even begun. It was that the rollout felt improvisational in exactly the way that undermines confidence in emergency spending. A federal loan of this size is supposed to be defended with paperwork, oversight, and a clear explanation of why the government is taking the risk. Instead, the public got a splashy announcement that made the whole arrangement look vulnerable to favoritism, insider access, and the kind of advance knowledge that can warp markets. The optics alone were enough to trigger a backlash. The substance made it worse. If the government wants to argue that it is rebuilding American manufacturing during a national emergency, it cannot do that by handing out an enormous loan in a way that leaves people wondering who got a heads-up and what exactly they were promised.

The likely fallout was never just about whether Kodak could actually execute the project. It was about whether the administration had already damaged the credibility of the decision by how it was announced and sold. That is the part that tends to linger. Even if later reviews were to sort out some of the transaction’s details or clear particular aspects of the process, the initial impression had already been set: impulsive, opaque, and open to capture. That impression is hard to shake, especially when the federal response to a pandemic is supposed to be the one place where clean process matters most. Senators and oversight-minded critics pressed for answers, and the questions were not unreasonable. Was the company vetted properly. Were the risks understood. Did anyone in the president’s orbit treat the announcement as a political win first and a public policy decision second. None of those questions could be waved away by rhetoric about leadership. In the end, the Kodak episode said as much about the Trump White House as it did about the company itself. A deal that was meant to symbolize national resilience instead looked like a taxpayer-backed stock-promo wrapped in industrial-policy jargon. That is a bad look in any year, but in the middle of a pandemic it was the kind of screwup that does not just embarrass a president for a news cycle. It confirms the worst suspicions about how the machine works.